Targeted delivery of antisense inhibitor of miRNA for antiangiogenesis therapy using cRGD-functionalized nanoparticles

Molecular Pharmaceutics

Volumn 8, Issue 1, 2011, Pages 250-259

  Liu, Xi Qiu ^a   Song, Wen Jing ^a   Sun, Tian Meng ^b   Zhang, Pei Zhuo ^c   Wang, Jun ^a  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^c Suzhou GenePharma Co Ltd   (China)

Author keywords

Anti miRNA therapy; Antiangiogenesis; CRGD; Targeted delivery

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYCLIC RGD PEPTIDE; DRUG CARRIER; HYALURONIC ACID; LIPOSOME; MACROGOL 2000; MATRIGEL; MICRORNA; MICRORNA 296; NANOPARTICLE; POLYCATION; SCATTER FACTOR; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANTIANGIOGENIC THERAPY; ANTISENSE THERAPY; ARTICLE; CELL MIGRATION; CHEMICAL MODIFICATION; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TARGETING; ENDOTHELIUM CELL; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VASCULARIZATION; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION;

ANIMALS; BLOTTING, WESTERN; CELL LINE; ENDOSOMAL SORTING COMPLEXES REQUIRED FOR TRANSPORT; FEMALE; HUMANS; LIPOSOMES; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; MODELS, THEORETICAL; NANOPARTICLES; OLIGONUCLEOTIDES, ANTISENSE; OLIGOPEPTIDES; PHOSPHOPROTEINS;

EID: 79952709094     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp100315q     Document Type: Article

References (47)

1. Bergers, G.; Benjamin, L. E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003, 3, 401-410. (Pubitemid 37328844)
2. Folkman, J. Tumor angiogenesis: therapeutic implications. New Engl. J. Med. 1971, 285, 1182-1186.
3. Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer I. 1990, 82, 4-6. (Pubitemid 20020880)
4. Kerbel, R. S. Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000, 21, 505-515. (Pubitemid 30137936)
5. Cooney, M. M.; van Heeckeren, W.; Bhakta, S.; Ortiz, J.; Remick, S.C. Drug Insight:Vascular disrupting agents and angiogenesiss - novel approaches for drug delivery. Nat. Clin. Pract. Oncol. 2006, 3, 682-692. (Pubitemid 44843126)
6. Zhe Wang, P. C. H. A nanocapsular combinatorial sequential drug delivery system for antiangiogenesis and anticancer activities. Biomaterials 2010, 31, 7115-7123.
7. Kerbel, R. S.; Kamen, B. A. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 2004, 4, 423-436. (Pubitemid 38745528)
8. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350, 2335-2342. (Pubitemid 38702844)
9. Mourelatos, Z. Small RNAs - The seeds of silence. Nature 2008, 455, 44-45.
10. Filipowicz, W.; Bhattacharyya, S. N.; Sonenberg, N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat. Rev. Genet. 2008, 9, 102-114.
11. Zhao, Y.; Srivastava, D. A developmental view of microRNA function. Trends Biochem. Sci. 2007, 32, 189-197. (Pubitemid 46603281)
12. Kota, J.; Chivukula, R. R.; O'Donnell, K. A.; Wentzel, E. A.; Montgomery, C. L.; Hwang, H. W.; Chang, T. C.; Vivekanandan, P.; Torbenson, M.; Clark, K. R.; Mendell, J. R.; Mendell, J. T. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137, 1005-1017.
13. Takeshita, F.; Patrawala, L.; Osaki, M.; Takahashi, R.; Yamamoto, Y.; Kosaka, N.; Kawamata, M.; Kelnar, K.; Bader, A. G.; Brown, D.; Ochiya, T. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol. Ther. 2010, 18, 181-187.
14. Suarez, Y.; Fernandez-Hernando, C.; Pober, J. S.; Sessa, W. C. Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ. Res. 2007, 100, 1164-1173. (Pubitemid 46684129)
15. Kuehbacher, A.; Urbich, C.; Zeiher, A. M.; Dimmeler, S. Role of dicer and drosha for endothelial MicroRNA expression and angiogenesis. Circ. Res. 2007, 101, 59-68. (Pubitemid 47094624)
16. Poliseno, L.; Tuccoli, A.; Mariani, L.; Evangelista, M.; Citti, L.; Woods, K.; Mercatanti, A.; Hammond, S.; Rainaldi, G. MicroRNAs modulate the angiogenic properties of HLTVECs. Blood 2006, 108, 3068-3071.
17. Wurdinger, T.; Tannous, B. A.; Saydam, O.; Skog, J.; Grau, S.; Soutschek, J.; Weissleder, R.; Breakefield, X. O.; Krichevsky, A. M. MiR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell 2008, 14, 382-393.
18. Vester, B.; Wengel, J. LNA (Locked nucleic acid): High-affinity targeting of complementary RNA and DNA. Biochemistry 2004, 43, 13233-13241. (Pubitemid 39391124)
19. Krutzfeldt, J.; Rajewsky, N.; Braich, R.; Rajeev, K. G.; Tuschl, T.; Manoharan, M.; Stoffel, M. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005, 438, 685-689.
20. Esau, C.; Davis, S.; Murray, S. F.; Yu, X. X.; Pandey, S. K.; Pear, M.; Watts, L.; Booten, S. L.; Graham, M.; McKay, R.; Subramaniam, A.; Propp, S.; Lollo, B. A.; Freier, S.; Bennett, C. F.; Bhanot, S.; Monia, B. P. MiR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006, 3, 87-98.
21. Howard, K. A. Delivery of RNA interference therapeutics using polycation-based nanoparticles. Adv. Drug Delivery Rev. 2009, 61, 710-720.
22. Chen, Y. C.; Sen, J.; Bathula, S. R.; Yang, Q.; Fittipaldi, R.; Huang, L. Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells. Mol. Pharm. 2009, 6, 696-705.
23. Li, S. D.; Chono, S.; Huang, L. Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol. Ther. 2008, 16, 942-946. (Pubitemid 351587105)
24. Li, S. D.; Chen, Y. C.; Hackett, M. J.; Huang, L. Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol. Ther. 2008, 16, 163-169.
25. Li, S. D.; Huang, L. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol. Pharmaceutics 2006, 3, 579-588. (Pubitemid 44639135)
26. Chono, S.; Li, S. D.; Conwell, C. C.; Huang, L. An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. J. Controlled Release 2008, 131, 64-69.
27. Chen, Y. C.; Wu, J. Z. J.; Huang, L. Nanoparticles Targeted With NGR Motif Deliver c-myc siRNA and Doxorubicin for Anticancer Therapy. Mol. Ther. 2010, 18, 828-834.
28. Jain, R. K. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat. Med. 2001, 7, 987-989. (Pubitemid 32937367)
29. Singh, S. R.; Grossniklaus, H. E.; Kang, S. J.; Edelhauser, H. F.; Ambati, B. K.; Kompella, U. B. Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene Ther. 2009, 16, 645-659.
30. Murphy, E. A.; Majeti, B. K.; Barnes, L. A.; Makale, M.; Weis, S. M.; Lutu-Fuga, K.; Wrasidlo, W.; Cheresh, D. A. Nanoparticlemediated drug delivery to tumor vasculature suppresses metastasis. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 9343-9348.
31. Nasongkla, N.; Shuai, X.; Ai, H.; Weinberg, B. D.; Pink, J.; Boothman, D. A.; Gao, J. M. cRGD-functionalized polymer micelles for targeted doxorubicin delivery. Angew. Chem., Int. Ed. 2004, 43, 6323-6327. (Pubitemid 40029462)
32. Schiffelers, R. M.; Koning, G. A.; ten Hagen, T. L. M.; Fens, M. H. A. M.; Schraa, A. J.; Janssen, A. N. P. C. A.; Kok, R. J.; Molema, G.; Storm, G. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J. Controlled Release 2003, 91, 115-122. (Pubitemid 37288882)
33. Fang, N.; Wang, J.; Mao, H. Q.; Leong, K. W.; Chan, V. BHEM-Chol/DOPE liposome induced perturbation of phospholipid bilayer. Colloids Surf., B 2003, 29, 233-245. (Pubitemid 36579352)
34. Trikha, M.; Zhou, Z.; Timar, J.; Raso, E.; Kennel, M.; Emmell, E.; Nakada, M. T. Multiple roles for platelet GPIIb/IIIa and alpha v beta 3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res. 2002, 62, 2824-2833. (Pubitemid 34525767)
35. Wong, R. J.; Chan, M. K.; Yu, Z. K.; Ghossein, R. A.; Ngai, I.; Adusumilli, P. S.; Stiles, B. M.; Shah, J. P.; Singh, B.; Fong, Y. Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12. Clin. Cancer Res. 2004, 10, 4509-4516. (Pubitemid 38878895)
36. Donate, F.; Juarez, J. C.; Guan, X. J.; Shipulina, N. V.; Plunkett, M. L.; Tel-Tsur, Z.; Shaw, D. E.; Morgan, W. T.; Mazar, A. P. Peptides derived from the histidine-proline domain of the histidineproline-rich glycoprotein bind to tropomyosin and have antiangiogenic and antitumor activities. Cancer Res. 2004, 64, 5812-5817. (Pubitemid 39095581)
37. Varet, J.; Vincent, L.; Akwa, Y.; Mirshahi, P.; Lahary, A.; Legrand, E.; Opolon, P.; Mishal, Z.; Baulieu, E. E.; Soria, J.; Soria, C.; Li, H. Dose-dependent effect of dehydroepiandrosterone, but not of its sulphate ester, on anglogenesis. Eur. J. Pharmacol. 2004, 502, 21-30. (Pubitemid 39311361)
38. Dechantsreiter, M. A.; Planker, E.; Matha, B.; Lohof, E.; Holzemann, G.; Jonczyk, A.; Goodman, S. L.; Kessler, H. N-methylated cyclic RGD peptides as highly active and selective alpha(v)beta(3) integrin antagonists. J. Med. Chem. 1999, 42, 3033-3040. (Pubitemid 29384038)
39. Sahay, G.; Alakhova, D. Y.; Kabanov, A. V. Endocytosis of nanomedicines. J. Controlled Release 2010, 145, 182-195.
40. Wang, Y. C.; Liu, X. Q.; Sun, T. M.; Xiong, M. H.; Wang, J. Functionalized micelles from block copolymer of polyphosphoester and poly(epsilon-caprolactone) for receptor-mediated drug delivery. J. Controlled Release 2008, 128, 32-40.
41. Stern, K. A.; Smit, G. D. V.; Place, T. L.; Winistorfer, S.; Piper, R. C.; Lill, N. L. Epidermal growth factor receptor fate is controlled by Hrs tyrosine phosphorylation sites that regulate Hrs degradation. Mol. Cell. Biol. 2007, 27, 888-898. (Pubitemid 46174554)
42. Bache, K. G.; Raiborg, C.; Mehlum, A.; Stenmark, H. STAM and Hrs are subunits of a multivalent ubiquitin-binding complex on early endosomes. J. Biol. Chem. 2003, 278, 12513-12521. (Pubitemid 36800240)
43. Grant, D. S.; Kinsella, J. L.; Fridman, R.; Auerbach, R.; Piasecki, B. A.; Yamada, Y.; Zain, M.; Kleinman, H. K. Interaction of endothelial-Cells with a laminin-a chain peptide (sikvav) in vitro and induction of angiogenic behavior in vivo. J. Cell. Physiol. 1992, 153, 614-625.
44. Ponce, M. L. In Vitro Matrigel angiogenesis assays. In Angiogenesis protocols; Murray, J. C., Ed.; Humana Press: Totowa, NJ, 2001; pp 205-209.
45. Malinda, K. M. In vivo Matrigel migration and angiogenesis assays. In Angiogenesis protocols; Murray, J. C., Ed.; Humana Press: Totowa, NJ, 2001; pp 47-52.
46. Chung, I.; Wong, N. K.; Flynn, G.; Yu, W. D.; Johnson, C. S.; Trump, D. L. Differential antiproliferative effects of calcitriol on tumor-derived and matrigel-derived endothelial cells. Cancer Res. 2006, 66, 8565-8573. (Pubitemid 44449170)
47. Morikawa, S.; Baluk, P.; Kaidoh, T.; Haskell, A.; Jain, R. K.; McDonald, D. M. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 2002, 160, 985-1000. (Pubitemid 34224587)